Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...

Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Chronological aging is a major risk factor for many neurodegenerative disorders affecting both the brain and the eye, including Alzheimer’s disease, ...

Medically reviewed by Matthew Wosnitzer, MD Managing complement 3 glomerulopathy involves several treatment options aimed at ...

Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane ...